Plants used in medicines and foods in osteoporosis: mechanistic insights into bone-remodeling homeostasis and clinical evidence
Abstract
Osteoporosis (OP) arises from the progressive uncoupling of bone remodeling, in which osteoclastic resorption exceeds osteoblastic formation under the combined influence of estrogen deficiency, nutrient insufficiency, oxidative stress, chronic inflammation, and age-related stem-cell decline. Although current antiresorptive and anabolic drugs improve bone mineral density (BMD), their long-term use is constrained by adverse effects, limited impact on bone microarchitecture, and suboptimal patient adherence. Plants used in medicines and foods (PMF), characterized by their dietary origin, multi-metabolite composition, and favorable safety profile, have emerged as promising candidates for sustained OP management. Accumulating evidence indicates that PMF metabolites, including flavonoids, polysaccharides, glycosides, and coumarins, exert coordinated osteoprotective effects by enhancing osteogenic pathways (Wnt/β-catenin, BMP/SMAD), suppressing osteoclastogenic signaling (RANKL/NFATc1/NF-κB), modulating endocrine axes, reshaping the gut-bone and immune microenvironment, and improving aging-related bone marrow-derived mesenchymal stem cell (BMSC) dysfunction. This review synthesizes current mechanistic and clinical evidence supporting PMF-based interventions and highlights critical challenges and the need for large-scale randomized controlled trials (RCTs). These advances will be essential for translating PMF into evidence-based, globally applicable strategies for OP prevention and…
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.